BACKGROUND: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemoperfusion (HIPEC) are frequently used to treat appendiceal carcinomatosis. Some patients require multivisceral resection because of the volume of disease. It is unclear whether extent of CRS impacts survival in appendiceal carcinomatosis. METHODS: We analyzed 282 patients undergoing attempted CRS/HIPEC for appendiceal carcinomatosis. Patients were defined as having undergone Extensive CRS (n = 60) if they had >3 organ resections or >2 anastomoses; a subgroup of Extreme CRS patients (n = 10) had ≥5 organ resections and ≥3 anastomoses. Kaplan-Meier survival curves and multivariate Cox-regression models were used to identify prognostic factors affecting outcomes. RESULTS: Relative to the comparison group, patients undergoing Extensive CRS had a higher median peritoneal carcinomatosis index, operative duration, blood loss, and length of stay. No difference in completeness of cytoreduction, severe morbidity, or 60-day mortality was evident. Subgroup analysis of 10 patients undergoing extreme CRS likewise revealed no increase in severe morbidity or mortality. Median progression-free (PFS) and overall survival (OS) were 23.5 and 74 months in the comparison group; 18.5 (p = 0.086) and 51 (p = 0.85) months in the Extensive CRS group; and 40 months and not reached in the Extreme CRS subgroup. In a multivariable analysis, extent of CRS was not independently associated with PFS or OS. CONCLUSIONS: Extensive CRS is associated with greater OR time, blood loss, and length of stay, but is not associated with higher morbidity, mortality, or inferior oncologic outcomes in patients with appendiceal carcinomatosis.
BACKGROUND: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemoperfusion (HIPEC) are frequently used to treat appendiceal carcinomatosis. Some patients require multivisceral resection because of the volume of disease. It is unclear whether extent of CRS impacts survival in appendiceal carcinomatosis. METHODS: We analyzed 282 patients undergoing attempted CRS/HIPEC for appendiceal carcinomatosis. Patients were defined as having undergone Extensive CRS (n = 60) if they had >3 organ resections or >2 anastomoses; a subgroup of Extreme CRS patients (n = 10) had ≥5 organ resections and ≥3 anastomoses. Kaplan-Meier survival curves and multivariate Cox-regression models were used to identify prognostic factors affecting outcomes. RESULTS: Relative to the comparison group, patients undergoing Extensive CRS had a higher median peritoneal carcinomatosis index, operative duration, blood loss, and length of stay. No difference in completeness of cytoreduction, severe morbidity, or 60-day mortality was evident. Subgroup analysis of 10 patients undergoing extreme CRS likewise revealed no increase in severe morbidity or mortality. Median progression-free (PFS) and overall survival (OS) were 23.5 and 74 months in the comparison group; 18.5 (p = 0.086) and 51 (p = 0.85) months in the Extensive CRS group; and 40 months and not reached in the Extreme CRS subgroup. In a multivariable analysis, extent of CRS was not independently associated with PFS or OS. CONCLUSIONS: Extensive CRS is associated with greater OR time, blood loss, and length of stay, but is not associated with higher morbidity, mortality, or inferior oncologic outcomes in patients with appendiceal carcinomatosis.
Authors: John H Stewart; Perry Shen; Gregory B Russell; Robert F Bradley; Jonathan C Hundley; Brian L Loggie; Kim R Geisinger; Edward A Levine Journal: Ann Surg Oncol Date: 2006-03-14 Impact factor: 5.344
Authors: D Elias; C Honoré; R Ciuchendéa; V Billard; B Raynard; R Lo Dico; C Dromain; P Duvillard; D Goéré Journal: Br J Surg Date: 2008-09 Impact factor: 6.939
Authors: Richard P McQuellon; Gregory B Russell; Perry Shen; John H Stewart; Weston Saunders; Edward A Levine Journal: Ann Surg Oncol Date: 2007-11-20 Impact factor: 5.344
Authors: Niraj J Gusani; Sung W Cho; Christos Colovos; Songwon Seo; Jan Franko; Scott D Richard; Robert P Edwards; Charles K Brown; Matthew P Holtzman; Herbert J Zeh; David L Bartlett Journal: Ann Surg Oncol Date: 2007-12-12 Impact factor: 5.344
Authors: Omeed Moaven; Konstantinos I Votanopoulos; Perry Shen; Paul Mansfield; David L Bartlett; Greg Russell; Richard McQuellon; John H Stewart; Edward A Levine Journal: Ann Surg Oncol Date: 2019-11-12 Impact factor: 5.344
Authors: Boateng Kubi; Richard Nudotor; Nadege Fackche; Wasay Nizam; Jordan M Cloyd; Travis E Grotz; Keith F Fournier; Sean P Dineen; Benjamin D Powers; Jula Veerapong; Joel M Baumgartner; Callisia N Clarke; Sameer H Patel; Laura A Lambert; Daniel E Abbott; Kara A Vande Walle; Mustafa Raoof; Byrne Lee; Shishir K Maithel; Charles A Staley; Fabian M Johnston; Jonathan B Greer Journal: Ann Surg Oncol Date: 2021-01-28 Impact factor: 5.344
Authors: Michelle L Bryan; Nora C Fitzgerald; Edward A Levine; Perry Shen; John H Stewart; Konstantinos I Votanopoulos Journal: Am Surg Date: 2014-09 Impact factor: 0.688
Authors: Jerzy Mielko; Karol Rawicz-Pruszyński; Magdalena Skórzewska; Bogumiła Ciseł; Agnieszka Pikuła; Magdalena Kwietniewska; Katarzyna Gęca; Katarzyna Sędłak; Andrzej Kurylcio; Wojciech P Polkowski Journal: Cancers (Basel) Date: 2019-11-02 Impact factor: 6.639
Authors: Carissa A Low; Michaela Danko; Krina C Durica; Abhineeth Reddy Kunta; Raghu Mulukutla; Yiyi Ren; David L Bartlett; Dana H Bovbjerg; Anind K Dey; John M Jakicic Journal: JMIR Perioper Med Date: 2020-03-23